Meiragtx Holdings Plc MGTX

$8.46 -0.28 (-3.20%)

Valuation

Market cap
854,169,000
Revenue TTM
$81,390,000
Net income TTM
$-114,200,000
P/E (trailing)
11.48
P/E (forward)
28.91
Profit margin
-140.31%
Debt to equity
0.57

Trading

Volume
825,000
Avg volume
855,682
Day's range
$8.25 – $8.70
Shares out
97,731,000
Stochastic %K
14%
Beta
1.09
Analysts
Moderate Buy
Price target
$27.75

Price

Company profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as...

Show more

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
646 860 7985
Website
https://www.meiragtx.com
Address
655 Third Avenue, Suite 1115, New York, United States

Latest news

Stocktwits

Bogy99 Nov 17, 9:19 PM
$MGTX will a lower share price garner quicker take out scenario ? My guess is no. I think Meira knows what they have and their worth. Now with adequate capital , they won’t go for a discount. Minimum they would take is ~$40 per share. Do you think someone will pay 350+% premium today?? They should given the strength of the pipeline, but will they??
1 replies
ErnieWorthing84 Nov 17, 3:21 PM 0 replies
Sharkw Nov 17, 2:50 PM
$MGTX price dropping again :( why can’t Lilly or JJ buy them out
0 replies
slinghook67 Nov 17, 12:18 AM
$MGTX Another transaction from earlier today. $1.5b deal value for a single stand-alone preclinical asset. Preclinical. Let that sink in.
0 replies
slinghook67 Nov 16, 3:17 PM
$MGTX Great news for Ollin but this is pretty remarkable and once again speaks to how significantly undervalued Meira is. Ollin only has 2 assets, one is Phase 1 and the 2nd hasn't officially started Phase 3. And their lead asset, while showing very strong efficacy to date, if approved will enter a brutally competitive market and given that, their peak annual sales potential is falling in the range of $1.5b-$2B. And, they do not own any manufacturing assets. Again, this is fantastic news for Ollin but contrast this purchase price with the totality of Meira's enterprise assets and our current market cap, and one can only imagine what our buyout price will be if Bota-Vec and Xerostomia trend towards regulatory approval. Not to mention Parkinson's & Riboswitch.....
0 replies
ErnieWorthing84 Nov 14, 1:00 AM
$MGTX Gauntlet thrown
1 replies
Bogy99 Nov 13, 7:27 PM
$MGTX regarding RIX treatment. “ in the course of my career I have had 4 or 5 experiences where I saw something and said ‘that is freaking awesome ‘ this (MGTX RIX treatment) is something that I have to integrate in my practice “. KOL.
1 replies
Bogy99 Nov 13, 7:06 PM
$MGTX i don’t remember ever seeing this 100% response rate in Japan for XLrP. “PMDA has informally expressed interest in approval in Japan”. Wonder how big that market is???
0 replies